Efter markedsføring er rapporteret enkelte tilfælde af hypoglykæmi hos patienter, i samtidig behandling med metformin eller thiazolidinedion.
During post marketing experience, cases of hypoglycaemia have been reported in patients treated with repaglinide in combination with metformin or thiazolidinedione.